PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Singh JA et al. – Based upon indirect comparisons, anakinra seemed less efficacious than etanercept, adalimumab and rituximab and etanercept seemed to cause fewer withdrawals due to adverse events than adalimumab, anakinra and infliximab. Significant heterogeneity in characteristics of trial populations imply that these finding must be interpreted with caution. These findings can inform physicians and patients regarding their choice of biologic for treatment of RA.

Today in Rheumatology...keeping you current

Laboratory Tests to Assess Patients with Rheumatoid Arthritis: Advantages and Limitations
Rheumatic Disease Clinics of North America, 12/11/09

Radiographic Measures to Assess Patients with Rheumatoid Arthritis: Advantages and Limitations
Rheumatic Disease Clinics of North America, 12/11/09

Joint Counts to Assess Rheumatoid Arthritis for Clinical Research and Usual Clinical Care: Advantages and Limitations
Rheumatic Disease Clinics of North America, 12/11/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address